|
CA2243235C
(en)
|
1996-01-17 |
2010-08-10 |
Imperial College Innovations Limited |
Immunotherapy using cytotoxic t lymphocytes (ctl)
|
|
US6872518B2
(en)
|
1997-09-22 |
2005-03-29 |
University Of Rochester |
Methods for selecting polynucleotides encoding T cell epitopes
|
|
HK1038929B
(zh)
|
1998-07-31 |
2005-05-06 |
株式会社国际癌症免疫研究所 |
基於癌抑制基因wt1的产物的癌抗原
|
|
WO2000020445A2
(en)
|
1998-10-02 |
2000-04-13 |
Ludwig Institute For Cancer Research |
Tumor antigens and ctl clones isolated by a novel procedure
|
|
US6407063B1
(en)
*
|
1998-10-02 |
2002-06-18 |
Ludwig Institute For Cancer Research |
Tumor antigens and CTL clones isolated by a novel procedure
|
|
GB9823897D0
(en)
|
1998-11-02 |
1998-12-30 |
Imp College Innovations Ltd |
Immunotherapeutic methods and molecules
|
|
ATE407206T1
(de)
*
|
1998-11-10 |
2008-09-15 |
Univ Rochester |
Methoden zu herstellung von genbanken
|
|
EP1146869A2
(en)
|
1999-01-27 |
2001-10-24 |
University Of South Florida |
Inhibition of stat3 signal transduction for human cancer therapy
|
|
EP1118661A1
(en)
*
|
2000-01-13 |
2001-07-25 |
Het Nederlands Kanker Instituut |
T cell receptor libraries
|
|
US6797514B2
(en)
*
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US20030235908A1
(en)
*
|
2000-02-24 |
2003-12-25 |
Xcyte Therapies, Inc. |
Activation and expansion of cells
|
|
US7572631B2
(en)
*
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US20030119185A1
(en)
*
|
2000-02-24 |
2003-06-26 |
Xcyte Therapies, Inc. |
Activation and expansion of cells
|
|
US7541184B2
(en)
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
|
JP2003528605A
(ja)
|
2000-03-28 |
2003-09-30 |
ユニヴァーシティー オヴ ロチェスター |
ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法
|
|
ES2288952T3
(es)
*
|
2000-05-11 |
2008-02-01 |
Baylor Research Institute |
Composiciones y metodos para producir celulas presentadoras de antigenos.
|
|
US20020019048A1
(en)
*
|
2000-05-25 |
2002-02-14 |
Ronald Berenson |
Methods for restoring or enhancing T-cell immune surveillance following naturally or artificially induced immunosuppression
|
|
DE10112851C1
(de)
|
2001-03-16 |
2002-10-10 |
Gsf Forschungszentrum Umwelt |
Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
|
|
EP1435776A4
(en)
|
2001-09-24 |
2006-01-25 |
Univ Pittsburgh |
VACCINE AGAINST CANCER AND DIAGNOSTIC PROCEDURE AND REAGENTS
|
|
US20040175373A1
(en)
*
|
2002-06-28 |
2004-09-09 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
US20050084967A1
(en)
*
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
US7638122B2
(en)
*
|
2003-03-07 |
2009-12-29 |
University Of South Florida |
Stat3 antagonists and their use as vaccines against cancer
|
|
DE60334250D1
(de)
*
|
2003-05-08 |
2010-10-28 |
Life Technologies Corp |
Erzeugung und isolierung antigenspezifischer t-zellen
|
|
CA2539716A1
(en)
*
|
2003-09-22 |
2005-04-07 |
Xcyte Therapies, Inc. |
Compositions and methods to accelerate hematologic recovery
|
|
DE10344799A1
(de)
|
2003-09-26 |
2005-04-14 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
|
DE102004023187A1
(de)
|
2004-05-11 |
2005-12-01 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
|
WO2006031221A1
(en)
*
|
2004-09-13 |
2006-03-23 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Compositions comprising t cell receptors and methods of use thereof
|
|
PL1642905T3
(pl)
|
2004-10-02 |
2009-04-30 |
Immatics Biotechnologies Gmbh |
Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
|
|
WO2007044033A2
(en)
|
2004-12-07 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
|
|
DE102005013846A1
(de)
|
2005-03-24 |
2006-10-05 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
|
EP1717245B1
(en)
|
2005-04-26 |
2011-06-08 |
Immatics Biotechnologies GmbH |
T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof
|
|
DK1910521T3
(da)
|
2005-08-05 |
2011-02-07 |
Helmholtz Zentrum Muenchen |
Generering af allo-begrænsede, antigenspecifikke T-celler
|
|
EP1806358B1
(en)
|
2005-09-05 |
2010-03-17 |
Immatics Biotechnologies GmbH |
Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
|
|
EP1760089B1
(en)
|
2005-09-05 |
2009-08-19 |
Immatics Biotechnologies GmbH |
Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
|
|
CA2626238C
(en)
|
2005-10-17 |
2015-10-06 |
Memorial Sloan Kettering Cancer Center |
Wt1 hla class ii-binding peptides and compositions and methods comprising same
|
|
US9265816B2
(en)
|
2006-04-10 |
2016-02-23 |
Sloan Kettering Institute For Cancer Research |
Immunogenic WT-1 peptides and methods of use thereof
|
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
|
EP1932537A1
(en)
*
|
2006-12-12 |
2008-06-18 |
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Expression of transgenic T cell receptors in LAK-T cells
|
|
BRPI0813626A2
(pt)
|
2007-07-27 |
2014-12-23 |
Immatics Biotechnologies Gmbh |
Epitopos imunogênicos para a imunoterapia
|
|
DK2183361T3
(en)
|
2007-07-27 |
2015-07-27 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against brain tumors
|
|
ES2554981T3
(es)
|
2008-03-27 |
2015-12-28 |
Immatics Biotechnologies Gmbh |
Nueva inmunoterapia contra tumores neuronales y cerebrales
|
|
RS53872B2
(sr)
|
2008-05-14 |
2018-06-29 |
Immatics Biotechnologies Gmbh |
Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
|
|
US8748170B2
(en)
|
2008-07-25 |
2014-06-10 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Polypeptides derived from cyclin B1 and uses thereof
|
|
RS53782B1
(sr)
|
2008-10-01 |
2015-06-30 |
Immatics Biotechnologies Gmbh |
Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
|
|
CN102272153B
(zh)
|
2008-11-24 |
2015-04-15 |
德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 |
高亲和力t细胞受体及其应用
|
|
US8467973B2
(en)
*
|
2009-07-28 |
2013-06-18 |
Promising Future, Llc |
Pairing processes for preparing alloreactive cytotoxic T cells
|
|
GB0917094D0
(en)
|
2009-09-29 |
2009-11-11 |
Ucl Biomedica Plc |
T-cell receptor
|
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
|
GB201019331D0
(en)
|
2010-03-19 |
2010-12-29 |
Immatics Biotechnologies Gmbh |
Methods for the diagnosis and treatment of cancer based on AVL9
|
|
CA2861206C
(en)
|
2012-01-13 |
2021-07-06 |
Richard J. O'reilly |
Immunogenic wt-1 peptides and methods of use thereof
|
|
CN110078813B
(zh)
|
2013-01-15 |
2023-03-28 |
纪念斯隆凯特林癌症中心 |
免疫原性wt-1肽和其使用方法
|
|
US10815273B2
(en)
|
2013-01-15 |
2020-10-27 |
Memorial Sloan Kettering Cancer Center |
Immunogenic WT-1 peptides and methods of use thereof
|
|
TWI777194B
(zh)
|
2013-08-05 |
2022-09-11 |
德商伊瑪提克斯生物科技有限公司 |
新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一）
|
|
GB201319446D0
(en)
|
2013-11-04 |
2013-12-18 |
Immatics Biotechnologies Gmbh |
Personalized immunotherapy against several neuronal and brain tumors
|
|
GB201408255D0
(en)
|
2014-05-09 |
2014-06-25 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
|
|
GB201411037D0
(en)
|
2014-06-20 |
2014-08-06 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
|
|
EP3172325B1
(en)
|
2014-07-22 |
2023-06-28 |
The University of Notre Dame du Lac |
Molecular constructs and uses thereof
|
|
GB201501017D0
(en)
|
2014-12-23 |
2015-03-04 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
|
|
PL3545965T3
(pl)
|
2014-12-23 |
2021-12-27 |
Immatics Biotechnologies Gmbh |
Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (hcc) i innych rodzajów raka
|
|
FI3273986T3
(fi)
|
2015-03-27 |
2024-02-07 |
Immatics Biotechnologies Gmbh |
Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan
|
|
GB201505585D0
(en)
|
2015-03-31 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
|
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
|
GB201507719D0
(en)
|
2015-05-06 |
2015-06-17 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
|
|
EP3919507A3
(en)
|
2015-07-01 |
2022-01-12 |
Immatics Biotechnologies GmbH |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
CR20170579A
(es)
|
2015-07-06 |
2018-05-25 |
Immatics Biotechnologies Gmbh |
Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres.
|
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
|
GB201522667D0
(en)
|
2015-12-22 |
2016-02-03 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
|
|
GB201602918D0
(en)
|
2016-02-19 |
2016-04-06 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
|
|
CN116375797A
(zh)
|
2016-03-01 |
2023-07-04 |
伊玛提克斯生物技术有限公司 |
用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
|
|
GB201603987D0
(en)
|
2016-03-08 |
2016-04-20 |
Immatics Biotechnologies Gmbh |
Uterine cancer treatments
|
|
GB201604458D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against cancers
|
|
KR102411975B1
(ko)
|
2016-04-06 |
2022-06-22 |
이매틱스 바이오테크놀로지스 게엠베하 |
Aml 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
|
|
TWI796299B
(zh)
|
2016-08-26 |
2023-03-21 |
德商英麥提克生物技術股份有限公司 |
用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
|
|
TWI796314B
(zh)
|
2017-01-27 |
2023-03-21 |
德商英麥提克生物技術股份有限公司 |
用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
|
|
CN110913954A
(zh)
|
2017-03-03 |
2020-03-24 |
黑曜石疗法公司 |
免疫疗法的组合物和方法
|
|
CN110831961B
(zh)
|
2017-03-03 |
2024-01-02 |
黑曜石疗法公司 |
用于免疫疗法的cd19组合物和方法
|
|
EP3609530A1
(en)
|
2017-04-10 |
2020-02-19 |
Immatics Biotechnologies GmbH |
Peptides and combination thereof for use in the immunotherapy against cancers
|
|
US11427614B2
(en)
|
2017-04-10 |
2022-08-30 |
Immatics Biotechnologies Gmbh |
Peptides and combination thereof for use in the immunotherapy against cancers
|
|
WO2018189152A2
(en)
|
2017-04-10 |
2018-10-18 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
|
|
CN119080881A
(zh)
|
2017-07-07 |
2024-12-06 |
伊玛提克斯生物技术有限公司 |
用于肺癌(包括nsclc、sclc和其他癌症)免疫治疗的新型肽和肽组合物
|
|
WO2019007974A1
(en)
|
2017-07-07 |
2019-01-10 |
Immatics Biotechnologies Gmbh |
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
|
|
DE102018107224A1
(de)
|
2018-02-21 |
2019-08-22 |
Immatics Biotechnologies Gmbh |
Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
TW202016131A
(zh)
|
2018-05-16 |
2020-05-01 |
德商英麥提克生物技術股份有限公司 |
用於抗癌免疫治療的肽
|
|
JP2021526365A
(ja)
*
|
2018-05-18 |
2021-10-07 |
チルドレンズ ナショナル メディカル センターＣｈｉｌｄｒｅｎ’Ｓ Ｎａｔｉｏｎａｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ |
改善された標的化ｔ細胞療法
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
US10925947B2
(en)
|
2018-06-29 |
2021-02-23 |
Immatics Biotechnologies Gmbh |
A*03 restricted peptides for use in immunotherapy against cancers and related methods
|
|
TW202019955A
(zh)
|
2018-07-31 |
2020-06-01 |
德商英麥提克生物技術股份有限公司 |
B*07 限制肽和肽組合的抗癌免疫治療和相關方法
|
|
US11945850B2
(en)
|
2018-09-17 |
2024-04-02 |
Immatics Biotechnologies Gmbh |
B*44 restricted peptides for use in immunotherapy against cancers and related methods
|
|
TW202024121A
(zh)
|
2018-09-18 |
2020-07-01 |
德商英麥提克生物技術股份有限公司 |
A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
|
|
CN109294995B
(zh)
*
|
2018-09-30 |
2020-08-04 |
北京鼎成肽源生物技术有限公司 |
一种rfft1细胞
|
|
CN110408657B
(zh)
*
|
2018-09-30 |
2021-03-16 |
北京鼎成肽源生物技术有限公司 |
一种afft1细胞的构建方法
|
|
WO2020123716A1
(en)
|
2018-12-11 |
2020-06-18 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
|
TW202039535A
(zh)
|
2018-12-18 |
2020-11-01 |
德商英麥提克生物技術股份有限公司 |
B*08限制肽和肽組合物抗癌免疫治療和相關方法
|
|
KR20210149251A
(ko)
|
2019-03-08 |
2021-12-08 |
옵시디안 테라퓨틱스, 인크. |
조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
|
|
CN114174327A
(zh)
|
2019-03-08 |
2022-03-11 |
黑曜石疗法公司 |
用于可调整调控的cd40l组合物和方法
|
|
JP2022537670A
(ja)
|
2019-06-12 |
2022-08-29 |
オブシディアン セラピューティクス， インコーポレイテッド |
Ｃａ２の組成物および調整可能な制御方法
|
|
WO2020252404A1
(en)
|
2019-06-12 |
2020-12-17 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
DE102019121007A1
(de)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
MX2022002747A
(es)
|
2019-09-10 |
2022-04-06 |
Obsidian Therapeutics Inc |
Proteinas de fusion de ca2-il15 para regulacion ajustable.
|
|
MX2022008415A
(es)
|
2020-01-08 |
2022-08-08 |
Obsidian Therapeutics Inc |
Composiciones y metodos para la regulacion ajustable de la transcripcion.
|
|
JP2023525423A
(ja)
|
2020-01-15 |
2023-06-16 |
イマティクス バイオテクノロジーズ ゲーエムベーハー |
Ｐｒａｍｅに特異的に結合する抗原結合タンパク質
|
|
EP4168053A1
(en)
|
2020-06-22 |
2023-04-26 |
Obsidian Therapeutics, Inc. |
Compositions and methods for tunable regulation of cas nucleases
|
|
WO2022060806A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
|
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
|
DE102020125465A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的ｈｌａ展示肽
|
|
WO2022184805A1
(en)
|
2021-03-03 |
2022-09-09 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
|
|
BR112023022765A2
(pt)
|
2021-05-05 |
2024-01-02 |
Immatics Biotechnologies Gmbh |
Proteínas de ligação ao antígeno que ligam especificamente o prame
|
|
JP2024529467A
(ja)
|
2021-07-27 |
2024-08-06 |
イマティクス バイオテクノロジーズ ゲーエムベーハー |
Ｃｔ４５に特異的に結合する抗原結合タンパク質
|
|
WO2025021979A1
(en)
|
2023-07-27 |
2025-01-30 |
Immatics Biotechnologies Gmbh |
Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
|
|
WO2025040598A2
(en)
|
2023-08-18 |
2025-02-27 |
Immatics Biotechnologies Gmbh |
Peptides displayed by mhc for use in immunotherapy against different types of cancer
|